Skip to main content
HairCited

Spironolactone için Kadın Tipi Saç Dökülmesi

A

19 çalışmaya (2 meta-analyses, 4 RCTs), toplam 5,743 katılımcıyla dayanmaktadır. 16/19 çalışma olumlu etkiler göstermektedir.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dspironolactone\u0026condition\u003Dfemale\u002Dpattern\u002Dhair\u002Dloss'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Sonuç

Spironolactone is strongly supported by research as an effective option that may help women with female pattern hair loss, with both oral and topical formulations showing benefits in clinical trials.

  • 84% of studies show positive effects, including 4 RCTs focused on women
  • Both oral and topical formulations have demonstrated benefits
  • A dedicated meta-analysis confirms efficacy and safety in female pattern hair loss
  • Combination with minoxidil may offer enhanced results

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs: None Outcome: None Etki: None None

Popülasyon: women with androgenetic alopecia (female pattern hair loss)

Randomized Controlled Trial n=204 24 weeks Double-blind
Spironolactone versus Bicalutamide in female pattern hair loss: A randomised clinical trial.
Dose: Bicalutamide 50 mg/day; spironolactone 100 mg/day vs: Spironolactone 100 mg/day Outcome: Hair density and shaft diameter change at 24 … Etki: Frontal: +5.05 vs +3.13 hairs/cm2 (diff 1.92) P < 0.001 (frontal); P = 0.028

Popülasyon: Women 18-50 with Sinclair Grade II-V FPHL (India)

randomized controlled trial n=80 24 weeks Single-blind
Evaluation of the Efficacy and Safety of Topical Spironolactone versus Topical Minoxidil in the Treatment …
Dose: Group A: 1% topical spironolactone gel twice daily; Group B: 5% topical minoxidil gel twice daily vs: Placebo Etki: Both groups showed statistically significant improvement. Group A: 10 mild, 16 moderate, 2 excellent None
RCT n=48 24 weeks Double-blind
Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a …
Dose: Spironolactone 100 mg once daily vs: Placebo Etki: Terminal hair counts: 9.48 vs 5.32 hairs/cm2; hair diameter: 4.23 vs 2.96 μm; moderate-to-marked imp p=0.063 (terminal hair counts)
Randomized Controlled Trial n=240 520 weeks Open-label
Nutritional deficiencies after sleeve gastrectomy and Roux-en-Y gastric bypass at 10 years: secondary analysis of …
Dose: None vs: Laparoscopic Roux-en-Y gastric bypass (LRYGB) Outcome: Nutritional deficiency prevalence at 10 years Etki: Iron deficiency: LSG 14% vs LRYGB 41% p=0.017 (iron deficiency)

Popülasyon: Severely obese adults undergoing bariatric surgery

Review
Male and female pattern hair loss.
Dose: None vs: Placebo Etki: None None

Key Statistics

45

Çalışmalar

6441

Katılımcılar

Positive

A

Derece

Referenced Papers

Australian prescriber 2025 2 atıf
Journal of cosmetic … 2023 3 atıf
Clinical and experimental … 2020 20 atıf
Australian journal of … 2018 8 atıf
The Cochrane database … 2016 18 atıf
Clinical obstetrics and … 2015 9 atıf
Current problems in … 2015 8 atıf
International journal of … 2013
Skinmed 2010 33 atıf
Seminars in cutaneous … 2009 4 atıf
Duodecim; laaketieteellinen aikakauskirja 2006
The British journal … 2005 205 atıf
Journal of the … 2005 64 atıf

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Yaygın Kullanılan Dozajlar

hairloss:
100-200 mg/day (prescription)

Üst sınır: 200 mg/day (hair loss indication)

Araştırmalarda İncelenen Dozajlar

Dozaj Süre Etki N
None -- Neutral --
Bicalutamide 50 mg/day; spironolactone 100 mg/day 24 weeks Positive 204
Group A: 1% topical spironolactone gel twice daily; Group B: 5% topical minoxidil gel twice daily 24 weeks Positive 80
Spironolactone 100 mg once daily 24 weeks Positive 48
None 520 weeks Positive 240
None -- Positive --
Group A: topical finasteride 1% solution; Group B: topical spironolactone 5% solution; Group C: topi 16 weeks Positive 45
4 g -- Neutral --

En iyi alım zamanı: Once or twice daily with food; prescription required

Safety & Side Effects

Bildirilen Yan Etkiler

  • Menstrual irregularities
  • Breast tenderness
  • Hyperkalemia (elevated potassium levels)
  • Dizziness and orthostatic hypotension
  • Frequent urination

Bilinen Etkileşimler

  • ACE inhibitors and ARBs (increased hyperkalemia risk)
  • Potassium supplements and potassium-sparing diuretics (dangerous hyperkalemia)
  • NSAIDs (may reduce diuretic effectiveness and increase kidney risk)
  • Digoxin (spironolactone may increase digoxin levels)

Tolere edilebilir üst alım: 200 mg/day (hair loss indication)

Herhangi bir takviye kullanmaya başlamadan önce mutlaka sağlık uzmanınıza danışın.Herhangi bir takviye başlatmadan önce her zaman sağlık uzmanınıza danışın.

Frequently Asked Questions

Does Spironolactone help with Kadın Tipi Saç Dökülmesi?
Based on 45 studies with 6,441 participants, there is strong evidence from multiple clinical trials that Spironolactone may support Kadın Tipi Saç Dökülmesi management. Our evidence grade is A (Strong Evidence).
How much Spironolactone should I take for Kadın Tipi Saç Dökülmesi?
Studies have used various dosages. A commonly studied range is 100-200 mg/day (prescription). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Spironolactone?
Reported side effects may include Menstrual irregularities, Breast tenderness, Hyperkalemia (elevated potassium levels), Dizziness and orthostatic hypotension. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Spironolactone and Kadın Tipi Saç Dökülmesi?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 45 peer-reviewed studies with 6,441 total participants. The overall direction of effect is positive.

Related Evidence

Spironolactone diğer sağlık durumları için

FDA Sorumluluk Reddi: Bu ifadeler Gıda ve İlaç Dairesi (FDA) tarafından değerlendirilmemiştir. Bu web sitesindeki ürünler ve bilgiler herhangi bir hastalığı teşhis etmek, tedavi etmek, iyileştirmek veya önlemek amacıyla tasarlanmamıştır. Sunulan kanıt dereceleri, yayımlanmış hakemli araştırmalarımızın analizine dayanmaktadır ve tıbbi tavsiye niteliği taşımamaktadır. Herhangi bir takviye rejimine başlamadan önce her zaman sağlık uzmanınıza danışın.